P
pear bio
Biotechnology company that develops biomedical technologies for cancer treatment by testing patients' drug resistance
About pear bio
Pear Bio operates in the healthcare and biotechnology sector, focusing on cancer treatment and drug development. The company has developed a Functional Precision Medicine platform that combines biological insights with artificial intelligence to rapidly assess the efficacy of cancer treatments. This platform uses patient-derived tumor samples and microfluidic chips to model cancer progression in real-time, including metastasis, to identify potential therapeutics or targets. Pear Bio's technology also applies to immuno-oncology by combining patient tumor samples with matched immune cells to monitor immune cancer dynamics, such as immune cell infiltration and tumor cell killing, thereby measuring the efficacy of immunotherapies.
Read full description
The primary clients of Pear Bio include oncologists, pharmaceutical companies, and clinical researchers. Oncologists use the platform to narrow down treatment options for cancer patients, especially when existing approved treatments are insufficient. Pharmaceutical companies benefit by using the platform to weed out unpromising cancer drug candidates in the preclinical phase, saving both time and money. Clinical researchers leverage the platform for translational studies and to discover predictive biomarkers for therapies.
Pear Bio operates on a B2B (business-to-business) model, generating revenue through service contracts with healthcare providers, pharmaceutical companies, and research institutions. The company offers its platform as a service, providing detailed reports and insights based on the analysis of patient tumor samples and drug efficacy predictions.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- London, United Kingdom
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 59.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Precision Medicine, Clinical Trials, Tech for Biotech and Pharma, AI Drug Discovery, BIA Techbio UK
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning pear bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Dec 2023 | $271K | — | UK Innovation | — |
| SERIES A✓Equity / VC | May 2023 | $14M | $56M | Compound · Octopus Ventures · Hoxton Ventures · SOSV | ↗ |
Growth signals
Latest recorded traffic for pear bio is 1.1K monthly website visits, down 42.1% over the last three months. pear bio's team declined 18.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
UK Innovation
Series A6 investors entered at this stage
SOSV
Octopus Ventures
Compound
Hoxton Ventures
Crista Galli Ventures
Fly Ventures
Other known investors4 additional known investors
Aj Leon
Emerge Accelerator
Grow London
HaloHealth
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about pear bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See pear bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.